"Pharmaceutical Headlines" "Pharmaceutical Nobel Prize" revealed a number of "first" products on the list

(2020/10/30) 3-year deadline will come to Sapp Ace's eye drops are facing the risk of discontinuation; (Click on the title, can obtain the original text) "Pharmaceutical 1st time" 3-year deadline will be to Sapp Ace's eye drops face the risk of discontinuation on the evening of October 28th, Shapps issued a notice that the evaluation of the quality and efficacy of dicosine hydrants in accordance with the requirements of the State Drug Administration can not be completed within three years.
Same day, Sapp Ace's third-quarter results showed that operating income for the January-September period was RMB240 million, down 40.61 percent from a year earlier, while net profit attributable to shareholders of listed companies was RMB28 million, down 171.65 percent from a year earlier.
revenue, profit decline is mainly due to eye drops, large infusions and other products sales revenue decline.
headlines: In a short period of time, Sapp Ace's decline in performance may be difficult to reverse.
The Galien Foundation announced the winners of the 2020 Galeon Award today after the Pharmaceutical Nobel Prize was announced.
, known as the "Nobel Prize in Medicine", is recognized as the highest honor in the pharmaceutical and biomedical industries for outstanding scientific innovations to improve human health.
is the 50th anniversary of the Galen Awards, and since its inception in 1970, 268 biopharmaceutical products have been awarded, covering 18 therapeutic areas.
: The Galen Prize is chosen by a jury of Nobel laureates.
the rise of China's CRO industry thanks to the development of innovative drugs? Misunderstanding! China's CRO industry has developed rapidly, with a market size of US$6.8 billion in 2019.
at the same time, China's innovative drugs are also booming, the state at the policy level is also encouraging enterprises to carry out innovative drug research and development.
, many people think that the development of CRO industry has benefited from the increased demand for innovative drugs in China, and even likened the relationship between "selling water" and "mining gold".
, the development of innovative drugs in China is not the root cause of the rise of CRO industry.
: China's CRO and innovative drugs are not "selling water" and "gold mining" relationship.
"Health sector" registration to pay 2000 yuan service fee Yellow bull monopoly number source hospital Doo Zhiyong Sanjia hospital registration system to join face recognition technology, and can not solve the problem of yellow cattle to sell high prices to patients for a long time.
need to create malformations is not surprising if we do not balance limited quality resources.
hospitals in the technical level with the "Yellow" in the process of fighting wisdom, but also need to consider improving the management capacity of the registration system.
: Hospitals need to improve their system management capabilities.
(Mi Net) myeloma 10 billion market group of stag-by-deer original research drug frequency "de-tide" nearly two years, in the generic drug quality and efficacy of the evaluation project to promote the development of new drugs has made great stoic progress.
In 2019, the State Drug Administration approved five multiple myeloma treatment drugs, namely, the Danetoyu single anti-injection in Janssen-Cilag, Belgium, Zhengtianqing Pharmaceuticals, Qilu Pharmaceuticals' Lanadamine Capsules, Nanjing Synthe Dongyuan, Nanjing Zhengda Tianqing's injection of boron titazome.
From 2020 to the present, NMPA has approved four multiple myeloma treatment drugs, namely Suzhou Terry Pharmaceuticals, Zhengda Tianqing Pharmaceuticals, Stone Pharmaceuticals Group Ohi Pharmaceuticals' injection boron tezome, yangzijiang Pharmaceuticals Group's Lnadamine capsules.
: China's multiple myeloma market has surfaced.